Furthermore, metformin, the first‐line drug for treating obesity‐related T2D, activates AMPK and suppresses TGF‐β1/Smad3 signaling, suppressing abnormal ECM remodeling in WAT and ameliorating IR in individuals with obesity.253. Here, SMAD3 is linked to Obesity.